Martin Auster
Stock Analyst at UBS
(2.15)
# 2,775
Out of 4,876 analysts
47
Total ratings
51.61%
Success rate
4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $55.17 | +117.51% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $36.52 | +187.51% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $7.10 | +266.20% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $4.72 | +2,442.37% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $3.42 | +8,671.93% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $11.63 | +398.92% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $284.27 | -31.05% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $0.41 | +24,049.83% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $99.49 | -39.69% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $35.81 | +81.51% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $17.11 | +326.65% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.38 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $13.86 | +462.77% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.99 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $5.67 | +658.38% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $29.03 | +17.12% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $9.56 | +119.67% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $22.47 | -28.79% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $55.17
Upside: +117.51%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $36.52
Upside: +187.51%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $7.10
Upside: +266.20%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $4.72
Upside: +2,442.37%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $3.42
Upside: +8,671.93%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $11.63
Upside: +398.92%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $284.27
Upside: -31.05%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $0.41
Upside: +24,049.83%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $99.49
Upside: -39.69%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $35.81
Upside: +81.51%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $17.11
Upside: +326.65%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.38
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $13.86
Upside: +462.77%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $0.99
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $5.67
Upside: +658.38%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $29.03
Upside: +17.12%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $9.56
Upside: +119.67%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $22.47
Upside: -28.79%